Patents by Inventor Dwight A. Towler
Dwight A. Towler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210290822Abstract: An implant is provided comprising a substrate having one or more nanoceria coatings coated at least partially thereon, wherein the one or more nanoceria coatings comprise surface cerium having a 3+/4+ oxidation state ratio such that the one or more nanoceria coatings exhibit catalase mimetic activity, superoxide dismutase mimetic activity, or both. Methods are provided for forming a nanoceria coating. The coating has nanoceria having a surface cerium 3+/4+ oxidation state ratio such that such that the coating exhibits catalase mimetic activity, superoxide dismutase mimetic activity, or both. Also disclosed is a method of reducing degradation of an implant by placing nanoceria in proximity to a bone-implant interface.Type: ApplicationFiled: March 16, 2021Publication date: September 23, 2021Inventors: Sudipta SEAL, Soumen DAS, William SELF, Dwight TOWLER
-
Patent number: 11007303Abstract: An implant is provided comprising a substrate having one or more nanoceria coatings coated at least partially thereon, wherein the one or more nanoceria coatings comprise surface cerium having a 3+/4+ oxidation state ratio such that the one or more nanoceria coatings exhibit catalase mimetic activity, superoxide dismutase mimetic activity, or both. Methods are provided for forming a nanoceria coaling. The coating has nanoceria having a surface cerium 3+/4+ oxidation state ratio such that such that the coating exhibits catalase mimetic activity, superoxide dismutase mimetic activity, or both. Also disclosed is a method of reducing degradation of an implant by placing nanoceria in proximity to a bone-implant interface.Type: GrantFiled: October 6, 2016Date of Patent: May 18, 2021Assignees: University of Central Florida Research Foundation, Inc., Sanford Burnham Prebys Medical Discovery InstituteInventors: Sudipta Seal, Soumen Das, William Self, Dwight Towler
-
Publication number: 20190060519Abstract: An implant is provided comprising a substrate having one or more nanoceria coatings coated at least partially thereon, wherein the one or more nanoceria coatings comprise surface cerium having a 3+/4+ oxidation state ratio such that the one or more nanoceria coatings exhibit catalase mimetic activity, superoxide dismutase mimetic activity, or both. Methods are provided for forming a nanoceria coaling. The coating has nanoceria having a surface cerium 3+/4+ oxidation state ratio such that such that the coating exhibits catalase mimetic activity, superoxide dismutase mimetic activity, or both. Also disclosed is a method of reducing degradation of an implant by placing nanoceria in proximity to a bone-implant interface.Type: ApplicationFiled: October 6, 2016Publication date: February 28, 2019Inventors: Sudipta SEAL, Soumen DAS, William SELF, Dwight TOWLER
-
Patent number: 7060463Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding novel androgen receptor (AR) protein from Macaca mulatta. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of Macaca mulatta AR (rhAR) activity, purified proteins and fusion proteins which comprise all or a portion of the rhAR protein, transgenic mice comprising a transgene encoding the rhAR protein, as well as production of antibodies against AR, or epitopes thereof.Type: GrantFiled: May 3, 2002Date of Patent: June 13, 2006Assignee: Merck & Co., Inc.Inventors: Dwight A. Towler, Fang Chen
-
Publication number: 20040254105Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding novel androgen receptor (AR) protein from Macaca mulatta. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of Macaca mulatta AR (rhAR) activity, purified proteins and fusion proteins which comprise all or a portion of the rhAR protein, transgenic mice comprising a transgene encoding the rhAR protein, as well as production of antibodies against AR, or epitopes thereof.Type: ApplicationFiled: October 31, 2003Publication date: December 16, 2004Inventors: Dwight A. Towler, Fang Chen
-
Patent number: 6645974Abstract: Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular the method wherein the androgen receptor is antagonized in the prostate of a male patient or in the uterus of a female patient and agonized in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, arthritis and joint repair, alone or in combination with other active agents.Type: GrantFiled: July 25, 2002Date of Patent: November 11, 2003Assignee: Merck & Co., Inc.Inventors: John H. Hutchinson, Michael J. Breslin, Gideon A. Rodan, Soumya P. Sahoo, Mark E. Duggan, Shun-Ichi Harada, Azriel Schmidt, Wasyl Halczenko, Dwight A. Towler
-
Publication number: 20030065004Abstract: Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular the method wherein the androgen receptor is antagonized in the prostate of a male patient or in the uterus of a female patient and agonized in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, arthritis and joint repair, alone or in combination with other active agents.Type: ApplicationFiled: July 25, 2002Publication date: April 3, 2003Inventors: John H. Hutchinson, Michael J. Breslin, Gideon A. Rodan, Soumya P. Sahoo, Mark E. Duggan, Shun-Ichi Harada, Azriel Schmidt, Wasyl Halczenko, Dwight A. Towler
-
Patent number: 4778878Abstract: An octapeptide inhibitor of myristoylating enzymes is disclosed having an amino acid sequence as follows or a physiologically acceptable amide or salt derivative thereof: ##STR1##Type: GrantFiled: September 30, 1987Date of Patent: October 18, 1988Assignee: Washington UniversityInventors: Steven P. Adams, Dwight A. Towler, Jeffrey I. Gordon
-
Patent number: 4778877Abstract: An octapeptide inhibitor of myristoylating enzymes is disclosed having an amino acid sequence as follows or a physiologically acceptable amide or salt derivative thereof: ##STR1##Type: GrantFiled: September 30, 1987Date of Patent: October 18, 1988Assignee: Washington UniversityInventors: Steven P. Adams, Dwight A. Towler, Jeffrey I. Gordon
-
Patent number: 4740588Abstract: A peptide substrate for myristoylating enzymes is disclosed having an amino acid sequence selected from the group consisting of the following sequences or a physiologically acceptable amide or salt derivative thereof: ##STR1## wherein R=Ala, Asn, Gln or Ser;S=Ala, Arg, Gln, Glu, Phe or Ser;T=Ala or Lys;W=Ala or Ser;X=Ala, Tyr, or Lys;Y=Arg or Pro; andZ=Arg, Leu or Lys.Type: GrantFiled: October 29, 1986Date of Patent: April 26, 1988Assignee: Washington UniversityInventors: Steven P. Adams, Dwight A. Towler, Luis Glaser
-
Patent number: 4709012Abstract: An octapeptide inhibitor of myristoylating enzymes is disclosed having an amino acid sequence selected from the group consisting of the following sequences or a physiologically acceptable amide or salt derivative thereof: ##STR1## wherein R=Leu, Phe, Tyr or Val.Type: GrantFiled: August 7, 1986Date of Patent: November 24, 1987Assignee: Washington UniversityInventors: Steven P. Adams, Dwight A. Towler, Luis Glaser